Form 4: KalVista Pharmaceuticals Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, sold shares to cover tax withholding obligations related to the vesting of restricted stock units (RSUs) and performance stock units (PSUs).
Summary
- On August 17, 2024, Christopher Yea, the Chief Development Officer of KalVista Pharmaceuticals, exercised options to acquire 11,495 shares of common stock.
- These shares were acquired through the vesting of restricted stock units (RSUs) and performance stock units (PSUs).
- On August 19, 2024, Mr. Yea sold 7,102 shares at a weighted average price of $12.0133 per share, with prices ranging from $11.47 to $12.35.
- The sale was to cover tax withholding obligations associated with the vesting of the RSUs and PSUs and does not represent a discretionary transaction.
- Following these transactions, Mr. Yea directly owns 84,467 shares of KalVista Pharmaceuticals.
- The vesting schedules for the RSUs and PSUs are based on continued service and, in the case of PSUs, the achievement of performance metrics.
Sentiment
Score: 5
Explanation: The document primarily reflects routine executive stock transactions related to compensation. The sale of shares to cover tax obligations is neutral and doesn't necessarily indicate positive or negative sentiment.
Industry Context
Executive stock transactions are common and often related to compensation packages. Monitoring these transactions can provide insights into management's perspective on the company's value, though sales to cover tax obligations are generally not indicative of a change in sentiment.
Comparison to Industry Standards
- Executive compensation packages including RSUs and PSUs are standard practice in the pharmaceutical industry.
- Companies like BioCryst Pharmaceuticals and Ionis Pharmaceuticals also utilize stock-based compensation.
- The vesting schedules and performance metrics associated with these grants are typically aligned with long-term company goals and shareholder value creation.
Key Dates
| Date | Description |
|---|---|
| August 17, 2022 | Vesting Commencement Date for 1/16th of RSU shares. |
| November 17, 2022 | Vesting Commencement Date for 1/12th of RSU shares. |
| January 10, 2024 | Date of PSU grant to the Reporting Person. |
| February 17, 2024 | Vesting Commencement Date for 1/4th of PSU shares. |
| August 17, 2024 | Transaction date for acquisition of shares through RSU and PSU vesting. |
| August 19, 2024 | Transaction date for sale of shares to cover tax obligations. |
| August 21, 2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.